Proton Pump Inhibitors – Their Pharmacological Impact on the Clinical Management of Acid-Related Disorders

Abstract

Acid secretion or intragastric pH play a very important role in the pathophysiology of acid-related disorders such as peptic ulcer (PU), gastrooesophageal reflux disease (GERD) or nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal lesions. Proton pump inhibitors (PPIs) represent the most potent/effective antisecretory drugs for these indications. For the selection among the various agents (omeprazole/esomeprazole (CAS 73590-58-6/119141-88-7), pantoprazole (CAS 102625-70-7), lansoprazole (CAS103577-45-3), rabeprazole (CAS 117976-83-3)) some features of their pharmacokinetic (PK) and pharmacodynamic (PD) properties should be considered as the clinical outcome depends on systemic drug exposure (PK) and elevation of intragastric pH about certain threshold levels (PD).

The present review updates PK, PD and clinical data to provide some guidance between the PPIs which differ somewhat in their metabolic pattern and drug interaction potential. Based on 24-h intragastric pH assessments the relative potencies of the PPIs compared to omeprazole were in healthy volunteers (in GERD patients): 0.42 (0.59), 1.0 (0.8), 1.0 (1.0), 1.25 (1.25) and 2.0 (1.4) for pantoprazole, lansoprazole, omeprazole, esomeprazole and rabeprazole, respectively. In general, the clinical benefits of PPI are well documented but some patients can be regarded as non-responders and thus represent a challenge for future clinical research.

Key words

Esomeprazole - Helicobacter pylori infection - Lansoprazole - Omeprazole - Pantoprazole - Peptic ulcer - Proton pump inhibitors, pharmacodynamics, pharmacokinetics - Rabeprazole - Reflux disease

• References

• 1 Andriulli A, Annese V, Caruso N, Pilotto A, Accadia L, Niro AG et al Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses. Am J Gastroenterol. 2005; 100: 207-19
• 2 Arayne MS, Sultana N, Qureshi MS, Naseem S. Interaction studies of omeprazole with mefloquine, pyrimethamine and sulfadoxine. Pak J Pharm Sci. 2006; 19: 314-21
• 3 Ariizumi K, Ohara S, Koike T, Inomata Y, Iijima K, Sekine H et al Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. J Gastroenterol Hepatol. 2006; 21: 1428-34
• 4 Armstrong D. Intravenous proton pump inhibitor therapy: a rationale for use. Rev Gastroenterol Disord. 2005; 5 (Suppl 2) S18-S30
• 5 Diav-Citrin O, Arnon J, Shechtman S, Schaefer C, van Ton-ningen MR, Clementi M et al The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther. 2005; 21: 269-75
• 6 Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun AN. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther. 2005; 21: 677-86
• 7 Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut. 1992; 33: 118-24
• 8 Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29: 769-84
• 9 Bour B, Staub JL, Chousterman M, Labayle D, Nalet B, Nouel O et al Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther. 2005; 21: 805-12
• 10 Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C et al A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess. 2006; 10 (iii–xiii) 1-183
• 11 Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990; 99: 345-51
• 12 Bytzer P, Blum A, De Herdt D, Dubois D. The Trial Investigators Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004; 20: 181-8
• 13 Calabresi L, Pazzucconi F, Ferrara S, Di Paolo A, Tacca MD, Sirtori C. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in healthy volunteers. Pharmacol Res. 2004; 49: 493-9
• 14 Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP et al Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol. 2005; 100: 1696-1701
• 15 Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther. 2005; 22: 193-202
• 16 Castro Fernández M, García Díaz E, Larraona JL, Rodríguez Hornillo MC, Lamas Rojas E, Núñez Hospital D et al Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. Rev Esp Enferm Dig. 2006; 98: 170-9
• 17 Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007; 102: 1808-25
• 18 Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002; 41: 913-58
• 19 Devault KR, Johanson JF, Johnson DA, Liu S, Sostek MB. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol. 2006; 4: 852-9
• 20 Dorward S, Sreedharan A, Leontiadis GI, Howden CW, Moayyedi P, Forman D. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2006; 18 CD005415
• 21 Egan LJ, Myhre GM, Mays DC, Dierkhising RA, Kammer PP, Murray JA. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther. 2003; 17: 1521-8
• 22 Esplugues JV, Marti-Cabrera M, Ponce J. Safety of proton pump inhibitors. Med Clin (Barc.). 2006; 127: 790-5
• 23 Ferguson DD, DeVault KR. Medical management of gastroesophageal reflux disease. Expert Opin Pharmacother. 2007; 8: 39-47
• 24 Fisher L, Fisher A, Pavli P, Davis M. Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention. Aliment Pharmacol Ther. 2007; 25: 297-308
• 25 Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol. 2005; 11: 3091-8
• 26 Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?. lin Pharmacokinet. 2008; 47: 1-6
• 27 Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved?. Can J Gastroenterol. 2003; 17 (Suppl B) 36B-40B
• 28 Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007; 147: 553-62
• 29 Fujioka T, Yoshiiwa A, Okimoto T, Kodama M, Murakami K. Guidelines for the management of Helicobacter pylori infection in Japan: current status and future prospects. J Gastroenterol. 2007; 42 (Suppl 17) 3-6
• 30 Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T et al Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002; 72: 453-60
• 31 Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007; 8: 1199-210
• 32 García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007; 132: 498-506
• 33 Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R et al Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J Clin Gastroenterol. 2006; 40: 515-20
• 34 Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G et al Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. J Am Coll Cardiol. 2008; 51: 256-60
• 35 Gisbert JP, Khorrami S, Calvet X, Pajares JM. Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2004; 16: 89-99
• 36 Gisbert JP, Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis. Dig Liver Dis. 2004; 36: 253-9
• 37 Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?. Aliment Pharmacol Ther. 2005; 21: 795-804
• 38 Glatzel D, Abdel-Qader M, Gatz G, Pfaffenberger B. Panto-prazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion. 2007; 75 (Suppl 1) 69-78
• 39 Goh KL, Benamouzig R, Sander P, Schwan T. EMANCIPATE. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial — the EMANCIPATE study. Eur J Gastroenterol Hepatol. 2007; 19: 205-11
• 40 Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006; 4: 1452-8
• 41 Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007; 167: 950-5
• 42 Gurbel PA, Lau WC, Tantry US. Omeprazole —a possible new candidate influencing the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008; 51: 261-3
• 43 Harrias BN, West DS, Johnson J, Hong SH, Stowe CD. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan. Manag Care Pharm. 2004; 10: 449-55
• 44 Hellström PM, Vitols S. The choice of proton pump inhibitor: does it matter?. Basic Clin Pharmacol Toxicol. 2004; 94: 106-11
• 45 Höer A, Gothe H, Schiffhorst G, Sterzel A, Grass U, Häussler B. Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease. Pharmacoepidemiol Drug Saf. 2007; 16: 854-8
• 46 Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002; 16: 479-85
• 47 Holtmann G, Howden CW. Review article: management of peptic ulcer bleeding-the roles of proton pump inhibitors and Helicobacter pylori eradication. Aliment Pharmacol Ther. 2004; 19 (Suppl 1) 66-70
• 48 Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors — focus on rabeprazole. Aliment Pharmacol Ther. 2004; 20 (Suppl. 6) 11-9
• 49 Horn JR, Howden CW. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther. 2005; 22 (Suppl. 3) 20-4
• 50 Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther. 1990; 4: 25-33
• 51 Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C et al Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108: 2244-7
• 52 Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007; 56: 1291-5
• 53 Ishino Y, Sugano K. [Acid-suppressive strategy against gastroesophageal reflux diseases and non-erosive reflux diseases: the alternative of proton-pump inhibitors or H2 receptor antagonists]. Nippon Rinsho. 2007; 65: 891-4
• 54 Iwakiri K, Kawami N, Tanaka Y, Sano H, Kotoyori M, Sakamoto C. Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor. Nippon Rinsho. 2007; 65: 913-20
• 55 Jaworski T, Sarosiek I, Sostarich S, Roeser K, Connor M, Brotze S et al Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig Dis Sci. 2005; 50: 357-65
• 56 Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol. 2006; 98: 4-19
• 57 Ji S, Kim HS, Kim JW, Jee MK, Park KW, Uh Y et al Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. J Gastroenterol Hepatol. 2006; 21: 1381-7
• 58 Julapalli VR, Graham DY. Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Dig Dis Sci. 2005; 50: 1185-93
• 59 Junghard O, Hassan-Alin M, Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol. 2002; 58: 453-8
• 60 Kang BC, Yang CQ, Cho HK, Suh OK, Shin WG. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos. 2002; 23: 77-81
• 61 Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2007; 25: 617-28
• 62 Kawamura M, Ohara S, Koike T, Iijima K, Suzuki J, Kayaba S et al The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther. 2003; 17: 965-73
• 63 Kawamura M, Ohara S, Koike T, Iijima K, Suzuki H, Kayaba S et al Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol. 2007; 22: 222-6
• 63a Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008; 28: 951-9
• 64 Khuroo MS, Khuroo MS, Farahat KL, Kagevi IE. Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis. J Gastroenterol Hepatol. 2005; 20: 11-25
• 65 Kim JI, Cheung DY, Cho SH, Park SH, Han JY, Kim JK et al Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized, controlled trial. Dig Dis Sci. 2007; 52: 3371-6
• 66 Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T et al Relative potency of proton pump inhibitors — comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009; 65: 19-31
• 67 Kirsch C, Morgner A, Miehlke S. Relevance of cytochrome P450 polymorphisms in the treatment of Helicobacter pylori infection and gastroesophageal reflux disease. Curr Pharmacogenom. 2006; 4: 47-56
• 68 Klotz U. The changing target in the treatment of peptic ulcer: from pH to Hp. In: Gupta editor. Pharmacology and therapeutics in the New Millenium. New Delhi, India: 2001. p. 587-98
• 69 Klotz U. The interaction potential of proton pump inhibitors. Verdauungskrankheiten. 2002; 20: 26-31
• 70 Klotz U. Proton pump inhibitors — a pharmacological and clinical comparison. Verdauungskrankheiten. 2004; 22: 112-20
• 71 Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet. 2000; 38: 243-70
• 72 Klotz U. Impact of CYP2C19 polymorphisms for the clinical action of proton pump inhibitors (PPIs). Eur J Clin Pharmacol. 2009; 65: 1-2
• 73 Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004; 95: 2-8
• 74 Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther. 2006; 44: 297-302
• 75 Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut. 2006; 55: 1217-21
• 76 Kumar R, Tandon VR, Bano G, Kapoor B, Sharma S, Gupta Y. Comparative study of proton pump inhibitors for triple therapy in H. pylori eradication. Indian J Gastroenterol. 2007; 26: 100-1
• 77 Lanas A, García-Rodríguez LA, Arroyo MT, Gomollón F, Feu F, González-Pérez A et al Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006; 55: 1731-8
• 78 Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007; 23: 163-73
• 79 Lassen AT. Acid-related disorders and use of antisecretory medication. Dan Med Bull. 2007; 54: 18-30
• 80 Leontiadis GI, McIntyre L, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2004; 3 CD002094
• 81 Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia— a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther. 2005; 21: 1055-61
• 82 Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ. 2005; 330: 568 (Epub Jan 31)
• 83 Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2006; 25 CD002094.
• 84 Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007; 82: 286-96
• 85 Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004; 32: 821-7
• 86 Li ZS, Zhan XB, Xu GM, Cheng NN, Liao Z. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial. J Gastroenterol Hepatol. 2007; 22: 815-20
• 87 Lim PW, Goh KL, Wong BC. CYP2C19 genotype and the PPIs-focus on rabeprazole. J Gastroenterol Hepatol. 2005; 20 (Suppl) S22-8
• 88 Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole — a gastric proton pump inhibitor — on pentagastrin-stimulated acid secretion in man. Gut. 1983; 24: 270-6
• 89 Louw JA. Peptic ulcer disease. Curr Opin Gastroenterol. 2006; 22: 607-11
• 90 Lüth S, Teyssen S, Kölbel CB, Singer MV. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease – A pilot study. Z Gastroenterol. 2001; 39: 279-81
• 91 Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D et al Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007; 56: 772-81
• 92 Martin de Argila C. Safety of potent gastric acid inhibition. Drugs. 2005; 65 (Suppl 1) 97-104
• 93 McCarthy DM. Management of bleeding peptic ulcer: current status of intravenous proton pump inhibitors. Best. Pract Res Clin Gastroenterol. 2004; 18 (Suppl) 7-12
• 94 Megraud F. Update on therapeutic options for Helicobacter pylori-related diseases. Curr Infect Dis Rep. 2005; 7: 115-20
• 95 Metz DC, Inadomi JM, Howden CW, van Zanten SJ, Bytzer P. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol. 2007; 102: 642-53
• 96 Miura M, Satoh S, Tada H, Habuchi T, Suzuki T. Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes. Eur J Clin Pharmacol. 2006; 62: 113-7
• 97 Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M et al Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007; 26: 69-77
• 98 Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006; 367: 2086-100
• 99 Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet. 2007; 370: 1010-2
• 100 Morocutti A, Merrouche M, Bjaaland T, Humphries T, Mignon M. An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment Pharmacol Ther. 2006; 24: 1439-44
• 101 Murthy S, Keyvani L, Leeson S, Targownik LE. Intravenous versus high-dose oral proton pump inhibitor therapy after endoscopic hemostasis of high-risk lesions in patients with acute nonvariceal upper gastrointestinal bleeding. Dig Dis Sci. 2007; 52: 1685-90
• 102 Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf. 2006; 29: 119-32
• 103 Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers. Aliment Pharmacol Ther. 2007; 25: 501-10
• 104 Ofman JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002; 16: 261-73
• 105 Ohkusa T, Maekawa T, Arakawa T, Nakajima M, Fujimoto K, Hoshino E et al Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment Pharmacol Ther. 2005; 21: 1331-9
• 106 Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P et al Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis. 2005; 37: 741-50
• 107 Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken ‘on-demand’. Aliment Pharmacol Ther. 2007; 26: 195-204
• 108 Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006; 101: 1467-75
• 109 Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003; 17: 1507-14
• 110 Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol. 2006; 4: 130-42
• 111 Pettit M. Treatment of gastroesophageal reflux disease. Pharm World Sci. 2005; 27: 432-5
• 112 Peura DA, Gudmundson J, Siepmann N, Pilmer BL, Freston J. Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci. 2007; 52: 983-7
• 113 Pilliano PI, Kubler PA, Radford JM, Overland V. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust. 2000; 172: 16-8
• 114 Pilotto A, Franceschi M, Leandro G, Scarcelli C, D’Ambrosio LP, Paris F et al Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol. 2007; 13: 4467-72
• 115 Qiao HL, Hu YR, Tian X, Jia LJ, Gao N, Zhang LR et al Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur J Clin Pharmacol. 2006; 62: 107-12
• 116 Ramdani A, Mignon M, Samoyeau R. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. Gastroenterol Clin Biol. 2002; 26: 355-9
• 117 Robertson DJ, Larsson H, Friis S, Pedersen L, Baron JA, Sørensen HT. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007; 133: 755-60
• 118 Robinson M. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders. Aliment Pharmacol Ther. 2004; 20 (Suppl 6) 30-7
• 119 Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23 (Suppl 2) 2-8
• 120 Saito M, Yasui-Furukori N, Uno T, Takahata T, Sugawara K, Munakata A et al Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005; 59: 302-9
• 121 Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y et al CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res. 2001; 18: 721-7
• 122 Sánchez Garrido A. Omeprazole-induced acute cholestatic hepatitis. Gastroenterol Hepatol. 2007; 30: 54
• 123 Savarino V, Savarino E, Parodi A, Dulbecco P. Functional heartburn and non-erosive reflux disease. Dig Dis. 2007; 25: 172-4
• 124 Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet. 2007; 369: 1580-1
• 125 Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci. 2006; 51: 844-50
• 126 Schneeweiss S, Maclure M, Dormuth CR, Glynn RJ, Canning C, Avron J. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther. 2006; 79: 379-88
• 127 Scholten T, Teutsch I, Bohuschke M, Gatz G. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Clin Drug Invest. 2007; 27: 287-96
• 128 Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther. 2004; 76: 201-9
• 129 Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P et al Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther. 2005; 78: 627-34
• 130 Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol. 2008; 64: 233-52
• 131 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008; 64: 935-51
• 132 Shimatani T, Inoue M, Kuroiwa T, Xu J, Tazuma S, Horikawa Y et al Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry. Dig Dis Sci. 2005; 50: 1202-6
• 133 Shimatani T, Moriwaki M, Xu J, Tazuma S, Inoue M. Acid-suppressive effects of rabeprazole: comparing 10 mg and 20 mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. Dig Liver Dis. 2006; 38: 802-8
• 134 Shimizu M, Uno T, Yasui-Furukori N, Sugawara K, Tateishi T. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006; 62: 597-603
• 135 Sierra F, Suarez M, Rey M, Vela MF. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007; 26: 545-53
• 136 Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003; 48: 322-8
• 137 Spiegel BM, Farid M, Dulai GS, Gralnek IM, Kanwal F. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med. 2006; 119 (448) e27-e36
• 138 Spiegel BM, Dulai GS, Lim BS, Mann N, Kanwal F, Gralnek IM. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage. Clin Gastroenterol Hepatol. 2006; 4: 988-97
• 139 Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2004; 78: 290-301
• 140 Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci. 2008; 53: 385-93
• 141 Treiber G, Malfertheiner P, Klotz U. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Expert Opin Pharmacother. 2007; 8: 329-350
• 142 Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM et al Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008; 51: 1925-34
• 143 Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. Br. J Clin Pharmacol. 2006; 61: 309-14
• 144 Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F et al Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007; 146: 556-63
• 145 Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004; 20: 99-107
• 146 Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101: 1900-20
• 147 van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2006; 3 CD002095
• 148 Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006; 79: 76-83
• 149 Waldum HL, Qvigstad G. Proton pump inhibitors and gastric neoplasia. Gut. 2007; 56: 1019-20
• 150 Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM et al St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther. 2004; 75: 191-7
• 151 Wang X, Fang JY, Lu R, Sun DF. A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori. Digestion. 2006; 73: 178-86
• 152 Warrington S, Baisley K, Dunn K, Boyce M, Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. Eur J Clin Pharmacol. 2006; 62: 685-91
• 153 Wong VW, Chan FK. 10 day sequential therapy was more effective than 10 day triple drug therapy for eradicating Helicobacter pylori infection. Evid Based Med. 2007; 12: 146
• 154 Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4’-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999; 9: 539-49
• 155 Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296: 2947-53
• 156 Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007; 133: 748-54
• 157 Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol. 2004; 44: 1223-9
• 158 Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S et al Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol. 2004; 57: 487-94
• 159 Yuan Y, Padol IT, Hunt RH. Peptic ulcer disease today. Nat Clin Pract. Gastroenterol Hepatol. 2006; 3: 80-9
• 160 Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut. 2007; 56: 475-9
• 161 Zapata-Colindres JC, Zepeda-Gómez S, Montaño-Loza A, Vázquez-Ballesteros E, de Jesús Villalobos J, Valdovinos-Andraca F. The association of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease. Can. J Gastroenterol. 2006; 20: 277-80
• 162 Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z et al Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Helicobacter. 2008; 13: 532-41
• 163 Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007; 56: 1353-7
• 164 Zullo A, Hassan C, Campo SM, Morini S. Bleeding peptic ulcer in the elderly: risk factors and prevention strategies. Drugs Aging. 2007; 24: 815-28